Israeli Drug Development Companies Are Poised for 505(b)(2) Development Process, Camargo Expert Says
Many Israeli pharmaceutical executives recently learned that the 505(b)(2) development process is an important tool that can significantly reduce costs and shorten the timeline for approval of new drugs, adding substantially to ROI.
Many Israeli pharmaceutical executives recently learned that the 505(b)(2) development process is an important tool that can significantly reduce costs and shorten the timeline for approval of new drugs, adding substantially to ROI.
“Israel is known for innovation, and Israeli developers offer a wide range of drug candidates with good market potential and an opportunity to gain U.S. FDA approval through 505(b)(2),” said Ken Phelps, president and CEO of Camargo Pharmaceutical Services and a leading international authority on the development process.
Speaking before an enthusiastic group of more than 40 C-level executives at an invitation-only drug development seminar in Tel Aviv Dec. 9, Phelps said development under 505(b)(2) is ideal for drugs making a change from a previously approved drug because it allows utilizing selected data from studies in the public domain.
“For new indications, drugs that enhance some aspect of an existing drug, drugs with dosage changes or new active ingredients, prodrugs, combination drugs or drug-device combinations, 505(b)(2) can be an attractive alternative,” Phelps said.
As head of a full-service organization specializing in 505(b)(2) development, Phelps stressed the importance of careful planning to evaluate both the scientific and commercial feasibility of proposed drug products.
“A step-by-step plan is essential to success,” Phelps said, “but success can mean a differentiated product with three, five or even seven years of market exclusivity and great potential for ROI.”
Phelps’ remarks provoked an enthusiastic response from the audience. “In two hours [our] team got answers to issues they were debating for months,” said Dr. Sharon Cohen-Vered, head of CMC at NeuroDerm.
Dr. Roni Mamluk, CEO at Chiasma added, "Even for a very experienced professional in the field, the event was an eye-opener."
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
